Clinical Trials Logo

Bowel; Ischemic, Acute clinical trials

View clinical trials related to Bowel; Ischemic, Acute.

Filter by:
  • None
  • Page 1

NCT ID: NCT06322862 Recruiting - Clinical trials for Bowel; Ischemic, Acute

Intraoperative Intestinal Perfusion Assessment by Fluorescence Angiography in Emergency Surgery

Start date: March 5, 2024
Phase: N/A
Study type: Interventional

This is a prospective, multicentre, non-randomized cohort study using real-time intraoperative visualization of bowel perfusion by indocyanine green (ICG) in all-cause bowel ischemia. At intraoperative finding of bowel ischemia, the initial intraoperative plan is noted and resection margins marked with a steril pen. A fluorescence angiography will be performed and the surgeon will note whether the suspected ischemic bowel is perfused, whether there is a change in the resection margins in centimeters, and if the intraoperative plan has changed. If resection is indicated and the strategy of choice is an anastomosis, a renewed fluorescence angiography will be performed to assess anastomotic perfusion.

NCT ID: NCT04577339 Not yet recruiting - Peritonitis Clinical Trials

The Best Care for Abdominal Emergencies Study

BCAE
Start date: December 1, 2020
Phase:
Study type: Observational

This is a single-centre retrospective cohort study utilising electronic hospital records. The aim of this study is to improve care for all patients with an intestinal emergency, irrespective of whether they have surgery or not. Data will be derived from electronic patient records collected as part of routine clinical patient care on all general adult wards (excluding maternity) between 2013 and 2020. We will then identify patients who had an emergency laparotomy, and those who had a laparoscopic procedure. We aim to identify 2 further groups where treatment is non-surgical (but could be medical or interventional radiology) or where treatment is considered futile, suggesting that an early focus on end of life care might be appropriate. The primary objective is to provide mortality rates for different treatment options, and analysis of short- and long-term outcomes. The secondary endpoints are to define patient sub-groups with similar health characteristics based on clinical data and an established risk index and to use statistical analysis to predict the risk of death for each patient group and treatment option, which will allow us to identify the best care pathways for each cluster.